Yayınlar & Eserler

Yayın Ağı
Makaleler 14
Tümü (14)
SCI-E, SSCI, AHCI (7)
SCI-E, SSCI, AHCI, ESCI (12)
ESCI (5)
Scopus (11)
TRDizin (4)

1. IGF Pathway Components as Potential Biomarkers in Gastric Cancer

CEYLANER B., ŞAHİN F., YILDIZ A., TAŞTEKİN D., GÖK A. F. K., BAYKAL A. T.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES , cilt.26, sa.22, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

2. Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

Kınıkoğlu O., Altıntaş Y. E., YILDIZ A., Akdağ G., Bal H., Yaşar Z. Y., et al.
Oncologist , cilt.30, sa.4, 2025 (SCI-Expanded) identifier identifier

3. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Güzel H. G., et al.
Journal of Chemotherapy , cilt.37, sa.6, ss.551-562, 2025 (SCI-Expanded) identifier identifier identifier

4. Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1

Dogan I., AHMED M. A., YILDIZ A., Vatansever S.
INDIAN JOURNAL OF SURGICAL ONCOLOGY , sa.3, ss.484-488, 2024 (ESCI) Sürdürülebilir Kalkınma identifier identifier

5. Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients

Dogan I., Yıldız A., Ahmed M. A., Vatansever S.
Indian Journal of Surgical Oncology , cilt.15, sa.3, ss.489-494, 2024 (ESCI) identifier

6. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

Kınıkoğlu O., Odabas H., Altıntaş Y. E., YILDIZ A., Çakan B., Akdağ G., et al.
Medicina (Kaunas, Lithuania) , cilt.60, sa.6, 2024 (SCI-Expanded) Creative Commons License identifier identifier identifier

7. Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study

Ferhatoglu F., Paksoy N., Khanmammadov N., YILDIZ A., AHMED M. A., Gülbas Z., et al.
Medicine , cilt.103, sa.8, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

8. Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or-Allergic Metastatic Ovarian Cancer

Khanmammadov N., Doğan İ., Okay N. S., YILDIZ A., Khishigsuren B., AZİZY A., et al.
Turk Onkoloji Dergisi , cilt.39, sa.2, ss.176-182, 2024 (ESCI) Sürdürülebilir Kalkınma identifier identifier

9. The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients

Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., et al.
Turkish Journal of Medical Sciences , cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier

10. Efficacy of Intrathecal Therapy In Breast Cancer Patients With Leptomeningeal Metastasis

Khanmammadov N., Dogan I., AHMED M. A., YILDIZ A., Nizam N., KHISHIGSUREN B., et al.
Eastern Journal of Medicine , cilt.29, sa.4, ss.503-508, 2024 (Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier

11. Kan Plazmasında Satellit-2 Tekrar Elementi DNA Dizilerinin Karakterizasyonu

ÖZGÜR E., YILDIZ A., BADEMLER S., GEZER U.
İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi , 2022 (Hakemli Dergi)

12. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study

PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., et al.
Medicine (United States) , cilt.101, sa.45, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

13. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.
CLINICAL CANCER INVESTIGATION JOURNAL , sa.4, ss.5-9, 2022 (ESCI) Creative Commons License Sürdürülebilir Kalkınma identifier

14. Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience

DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.
CLINICAL CANCER INVESTIGATION JOURNAL , sa.3, ss.25-29, 2022 (ESCI) Creative Commons License Sürdürülebilir Kalkınma identifier
Metrikler

Yayın

14

Yayın (WoS)

12

Yayın (Scopus)

11

Atıf (WoS)

1

H-İndeks (WoS)

1

Atıf (Scopus)

4

H-İndeks (Scopus)

1

Açık Erişim

5
BM Sürdürülebilir Kalkınma Amaçları